Oruka Therapeutics, Inc. 8K

Oruka Therapeutics reported Q2 2026 results, outlined substantial clinical and pipeline milestones for ORKA-001/002/004, and disclosed a $1.1 billion cash position expected to fund operations through an anticipated BLA filing for ORKA-001.

On August 10, 2026, Oruka Therapeutics, Inc. reported its second quarter 2026 financial results and provided a detailed corporate update, highlighting multiple upcoming clinical milestones for its lead biologic candidates ORKA-001 and ORKA-002, the planned initiation of a Phase 3 program for ORKA-001 in the first half of 2027, acceleration and initiation of several Phase 2 trials (EVERLAST-A/B, ORCA-SURGE, ORCA-SPLASH), plans to advance a new TL1A-targeting antibody ORKA-004 into the clinic in the fourth quarter of 2026 with combination studies starting in 2027, and confirming a strengthened cash position of $1.1 billion—bolstered by an upsized $700 million public equity offering in April 2026 and an expanded IL-23 license with Paragon Therapeutics—expected to fund operations through a planned BLA filing for ORKA-001 and continued development of ORKA-002 despite a growing R&D-driven net loss.

Filing Facts

CIK

907654

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-086933

Alert Tier

6